Robert W. Baird analyst Jonathan Komp maintained a Buy rating on VF (VFC – Research Report) on July 29 and set a price target of $56.00. The company’s shares closed last Friday at $44.68, close to its 52-week low of $43.08.
According to TipRanks.com, Komp is a 5-star analyst with an average return of 11.4% and a 48.5% success rate. Komp covers the Consumer Goods sector, focusing on stocks such as Canada Goose Holdings, Wolverine World Wide, and Columbia Sportswear.
Currently, the analyst consensus on VF is a Moderate Buy with an average price target of $51.94, implying a 9.3% upside from current levels. In a report issued on July 21, BTIG also maintained a Buy rating on the stock with a $67.00 price target.
Based on VF’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.82 billion and net profit of $80.84 million. In comparison, last year the company earned revenue of $2.58 billion and had a net profit of $89.52 million.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VFC in relation to earlier this year. Most recently, in May 2022, Richard Carucci, a Director at VFC bought 7,636 shares for a total of $287,114.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
V.F. Corporation is one of the world’s largest apparel, footwear, and accessories retailer. The company engages in the design, procurement, production, marketing and distribution of lifestyle apparel, footwear, and accessories for men, women and children. It owns some of the world’s most popular and premium brands including Timberland, North Face, Icebreaker, Vans, Smartwool, Altra, Kipling, Napapijri, JanSport, Eastpak.
Read More on VFC:
- Mizuho Securities Maintains a Hold Rating on Fortive (FTV)
- Ultragenyx Pharmaceutical (RARE) Gets a Hold Rating from Robert W. Baird
- Masco (MAS) Gets a Buy Rating from Robert W. Baird
- Alnylam Pharma (ALNY) Gets a Hold Rating from SVB Securities
- Robert W. Baird Maintains Their Buy Rating on Neurocrine (NBIX)